An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

By Gottlieb A. B.   Strober B.   Krueger J. G.   Rohane P.   Zeldis J. B.   Hu C. C.   Kipnis C.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1529-1538

Informa Healthcare

Access to resources Recommend Favorite

Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from a 1-Year, Multicentre, Open-Label, Single-Arm Study in a Clinical Setting

By Vender Ronald   Lynde Charles   Ho Vincent  

Applied Health Economics and Health Policy, Vol. 10, Iss. 5, 2012-09 ,pp. : 343-353

Adis International

Access to resources Recommend Favorite

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 6, 2015-06 ,pp. : 1148-1155

John Wiley & Sons Inc

Access to resources Recommend Favorite

Canakinumab for the Treatment of Children With Colchicine‐Resistant Familial Mediterranean Fever: A 6‐Month Open‐Label, Single‐Arm Pilot Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 11, 2014-11 ,pp. : 3241-3243

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study

By Vena Gino A.   Galluccio Antonia   Pezza Michele   Vestita Michelangelo   Cassano Nicoletta  

Journal of Dermatological Treatment, Vol. 23, Iss. 4, 2012-08 ,pp. : 255-260

Informa Healthcare

Access to resources Recommend Favorite